Tracers / [225Ac]Ac-DOTA-PKU525
[225Ac]Ac-DOTA-PKU525
Also written as [Ac-225]Ac-DOTA-PKU525
- Radionuclide
- Ac-225 t½ 14284.8 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- FAP-targeting antibody (DOTA-conjugated)
- Target / mechanism
- Fibroblast activation protein (FAP) PMID 39474138
- Clinical application
- Targeted alpha therapy for FAP-expressing tumors (preclinical) PMID 39474138
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | SPE | 80 | — | p-SCN-Bn-DOTA Macrocyclics | 39474138 2023 Chem Biomed Imaging The procedure of 225Ac radiolabeling was explored with the one-step labeling method illustrated in Figure 1A. — an RCY of 80% was achieved when the molar amount of PKU-DOTA with DAR 7.72 was 3.2 nmol, PKU-DOTA with DAR 3.87 was 6.4 nmol, and PKU-DOTA with DAR1.85 was 12.8 nmol |
Need this precursor?We can point you to suppliers for [225Ac]Ac-DOTA-PKU525, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 39474138. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty.